Minutes: Draft

Guideline Development Group Meeting

| Date and Time: | Type 1 Diabetes in Adults Update  
Guideline Development Group meeting  
Tuesday 14\textsuperscript{th} May 2013  
10:00-16:00 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>National Clinical Guidelines Centre</td>
</tr>
</tbody>
</table>
| Present:       | GDG Members  
Prof Stephanie Amiel  
Mr Arthur Durrant  
Dr Michael Flynn  
Prof Roger Gadsby  
Dr Peter Hammond  
Mr Mike Kendall  
Ms Vicky Ruszala  
Dr Stuart Smellie  
Ms Perdy Van Den Berg |
|                | Technical Team  
Dr Bernard Higgins  
Dr Gus Brookes  
Ms Nancy Turnbull  
Ms Rachel O’Mahony  
Mr Jonathan Nyong  
Mr Chris Kiff  
Ms Rhosyn Harris  
Ms Nancy Pursey  
Mr Alex Allen |
| Apologies:     | Ms Vibhuti Mistry  
Dr Henrietta Mulnier |

In attendance:  

NICE Staff:  
Claire Ruiz (nee Turner) NICE Commissioning Manager  
Bhash Naidoo NICE Senior Technical Adviser
Notes

1. **Welcome, introduction and apologies**

The Chair welcomed the group to the sixth meeting. The chairman introduced Dr Gus Brookes who is joining the NCGC technical team and Nancy Pursey, senior project manager, who is taking over from Nancy Turnbull. The GDG expressed their gratitude to Nancy Turnbull for project managing the guideline thus far. Debra Lake has resigned from her role as GDG member. Apologies were received from Vibhuti Mistry and Henrietta Mulnier.

2. **Minutes of the previous meeting**

The GDG reviewed the minutes which were accepted as a true and accurate record of the meeting.

3. **Declarations of interest**

Mike Kendall declared that he has volunteered to test a smartphone app for self-monitoring. It was agreed that Mike can declare and participate for the question looking at technologies for self-monitoring.

Roger Gadsby previously declared an interest related to Novo Nordisk and was not present for the reviews of mixed insulin or once vs. twice daily insulin.

Vicky Ruszala previously declared interests relating to Lily and Boehringer, and was present but did not participate in making recommendations for insulin.

4. **Evidence review: adjunctive non-insulin therapies**

Clinical and cost effectiveness evidence was presented. The GDG discussed the evidence and made recommendations.

5. **Evidence review: continuous glucose monitoring (CGM) vs. self monitoring (SMBG) of blood glucose**

An updated evidence report was presented. Draft recommendations were discussed and will be revisited when the results of the model are available.

6. **Evidence review: mixed insulin**

The clinical and cost effectiveness evidence for mixed insulin was presented and the evidence was discussed. Further work is needed on the evidence report before recommendations can be made. The report will be updated and presented again at a later GDG meeting.

7. **Evidence review: once vs. twice daily insulin**

Clinical and cost effectiveness evidence was presented and discussed. Recommendations will be drafted following further consideration of the evidence when the results of the network meta analysis are available.

8. **Review protocols**

The GDG reviewed the protocol for the HbA1c targets question and updated it.
Notes

9. **Date, time and venue of the next meeting**

The chair thanked participants for attending and confirmed the date of the next meeting.

The next GDG meeting takes place on Tuesday 18th June 2013, 1000 – 1600.
Venue: National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ